ANKRD37

Summary

ANKRD37 (ankyrin repeat domain 37, HGNC:29593) is a protein-coding gene on chromosome 4q35.1, encoding Ankyrin repeat domain-containing protein 37 (Q7Z713).

Located in cytosol; mitochondrion; and nucleoplasm.

Source: NCBI Gene 353322 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 56 total — 7 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_181726

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29593
Approved symbol	ANKRD37
Name	ankyrin repeat domain 37
Location	4q35.1
Locus type	gene with protein product
Status	Approved
Aliases	Lrp2bp
Ensembl gene	ENSG00000186352
Ensembl biotype	protein_coding
OMIM	619021
Entrez	353322

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 2 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000335174, ENST00000506424, ENST00000507479, ENST00000507753, ENST00000511311, ENST00000511393

RefSeq mRNA: 1 — MANE Select: NM_181726 NM_181726

CCDS: CCDS3841

Canonical transcript exons

ENST00000335174 — 5 exons

Exon	Start	End
ENSE00001334348	185399570	185399773
ENSE00001334461	185400017	185400241
ENSE00001334462	185396841	185396950
ENSE00003654647	185398937	185399028
ENSE00003663677	185397150	185397302

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 98.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.6728 / max 251.2474, expressed in 1643 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50882	5.9247	1012
50879	2.8517	1179
50880	0.6647	332
50881	0.2316	105

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.81	gold quality
oocyte	CL:0000023	98.64	gold quality
secondary oocyte	CL:0000655	96.65	gold quality
popliteal artery	UBERON:0002250	96.45	gold quality
tibial artery	UBERON:0007610	96.43	gold quality
bronchial epithelial cell	CL:0002328	96.36	gold quality
bronchus	UBERON:0002185	95.94	gold quality
pericardium	UBERON:0002407	95.51	gold quality
aorta	UBERON:0000947	95.30	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.95	gold quality
ascending aorta	UBERON:0001496	94.26	gold quality
tibialis anterior	UBERON:0001385	94.12	silver quality
amniotic fluid	UBERON:0000173	93.97	gold quality
thoracic aorta	UBERON:0001515	93.88	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.74	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	93.21	gold quality
right uterine tube	UBERON:0001302	93.13	gold quality
adenohypophysis	UBERON:0002196	93.13	gold quality
esophagus mucosa	UBERON:0002469	93.09	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.98	gold quality
left ovary	UBERON:0002119	92.95	gold quality
vagina	UBERON:0000996	92.46	gold quality
pituitary gland	UBERON:0000007	92.05	gold quality
descending thoracic aorta	UBERON:0002345	91.96	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.95	gold quality
biceps brachii	UBERON:0001507	91.74	gold quality
right ovary	UBERON:0002118	91.58	gold quality
deltoid	UBERON:0001476	91.40	silver quality
gastrocnemius	UBERON:0001388	91.32	gold quality
muscle of leg	UBERON:0001383	91.17	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-CURD-7	yes	383.09
E-GEOD-124858	yes	358.24
E-ENAD-21	yes	341.29
E-HCAD-11	yes	19.20
E-ANND-3	yes	7.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AFF4, BRD4, CDK7, CDK8, CDK9, H4C2, HIF1A, MED1, MED26, POLR2A, SUPT5H

miRNA regulators (miRDB)

20 targeting ANKRD37, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-21-5P	99.46	70.54	1035
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-3614-5P	99.30	65.25	837
HSA-MIR-320A-5P	98.88	66.75	1248
HSA-MIR-412-3P	98.86	66.89	712
HSA-MIR-6754-3P	98.84	66.60	889
HSA-MIR-6868-3P	98.63	69.64	2259
HSA-MIR-5011-3P	98.63	64.81	638
HSA-MIR-1237-3P	98.55	67.65	1423
HSA-MIR-1248	98.47	67.54	1314
HSA-MIR-6837-3P	98.42	66.71	1149
HSA-MIR-499B-5P	98.35	68.39	988
HSA-MIR-338-3P	98.14	67.38	1137
HSA-MIR-634	97.74	67.11	818
HSA-MIR-22-5P	97.67	68.92	1355

Literature-anchored findings (GeneRIF, showing 2)

• ANKRD37 is a direct HIF-1 target that is highly induced in hypoxia. (PMID:19491311)
• A causal association of ANKRD37 with human hippocampal volume. (PMID:36195640)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ankrd37	ENSDARG00000056376
mus_musculus	Ankrd37	ENSMUSG00000050914
rattus_norvegicus	Ankrd37	ENSRNOG00000031335

Paralogs (1): ANKRD42 (ENSG00000137494)

Protein

Protein identifiers

Ankyrin repeat domain-containing protein 37 — Q7Z713 (reviewed: Q7Z713)

Alternative names: Low-density lipoprotein receptor-related protein 2-binding protein

All UniProt accessions (2): D6RFF5, Q7Z713

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Mainly expressed in testis, small intestine, colon, blood leukocytes and in pancreatic adenocarcinoma cells.

Post-translational modifications. Ubiquitinated by the CRL2(FEM1B) complex, leading to its degradation.

RefSeq proteins (1): NP_859077* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR050776	Ank_Repeat/CDKN_Inhibitor	Family

Pfam: PF12796

UniProt features (6 total): repeat 3, chain 1, short sequence motif 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z713-F1	71.93	0.33

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 192 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, MENSE_HYPOXIA_UP, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, chr4q35, HIF1_Q3, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, COATES_MACROPHAGE_M1_VS_M2_DN, GFI1_01, IK3_01, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP, TGGAAA_NFAT_Q4_01, BOYLAN_MULTIPLE_MYELOMA_C_D_UP, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, LEE_RECENT_THYMIC_EMIGRANT

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): male germ cell nucleus (GO:0001673), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	2
intracellular membrane-bounded organelle	2
binding	1
germ cell nucleus	1
nuclear lumen	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1034 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANKRD37	FEM1B	Q9UK73	698
ANKRD37	BNIP3	Q12983	529
ANKRD37	CFAP96	A7E2U8	443
ANKRD37	MSS51	Q4VC12	436
ANKRD37	NDRG1	Q92597	394
ANKRD37	FAM149A	A5PLN7	379
ANKRD37	EGLN3	Q9H6Z9	378
ANKRD37	ELL2	O00472	375
ANKRD37	SNX25	Q9H3E2	364
ANKRD37	SPAG4	Q9NPE6	363
ANKRD37	PFKFB4	Q16877	355
ANKRD37	ERRFI1	Q9UJM3	355
ANKRD37	VGLL1	Q99990	353
ANKRD37	GYS1	P13807	351
ANKRD37	WSB1	Q9Y6I7	350

IntAct

11 interactions, top by confidence:

A	B	Type	Score
ANKRD37	HIF1AN	psi-mi:“MI:0915”(physical association)	0.560
ZNF76	ANKRD37	psi-mi:“MI:0915”(physical association)	0.560
ANKRD37	HIF1AN	psi-mi:“MI:0915”(physical association)	0.000
ZNF76	ANKRD37	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (3): ANKRD37 (Two-hybrid), ANKRD37 (Two-hybrid), ANKRD37 (Affinity Capture-RNA)

ESM2 similar proteins: A0MQH0, A4II29, A4IIX9, E9PTA2, O94826, P24786, Q0VC93, Q13507, Q16288, Q17QS6, Q25BN1, Q3ULA2, Q502M6, Q59H18, Q5GIG6, Q5IFJ9, Q5IS37, Q5IS82, Q5U5A6, Q5ZLX4, Q6DFV5, Q6GPR5, Q6GQW0, Q6TUI4, Q75Q39, Q7T3X9, Q7T3Y0, Q7TQP6, Q7Z6K4, Q7Z713, Q862Z2, Q8BPU7, Q8K4Q0, Q8N122, Q8VBX0, Q8WWX0, Q8WXK3, Q91987, Q91YD4, Q91ZA8

Diamond homologs: A0A0R4IQZ2, A7MB89, O43150, Q00653, Q0VC93, Q10728, Q28FJ2, Q2T9K6, Q3V096, Q4JHE0, Q569N2, Q5U464, Q6JAN1, Q6RI86, Q7SIG6, Q7XUW4, Q7Z713, Q7ZUV0, Q8CEF1, Q8N9B4, Q94A76, Q96JP0, Q96KQ7, Q9D119, Q9DBR7, Q9P2R3, Q9Z148, A2AQH4, A4II29, B2RR83, G3I6Z6, O00522, O13987, O14974, O60237, P46531, P83757, Q01705, Q02979, Q03017

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	7
Likely pathogenic	2
Uncertain significance	38
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (9)

Variant ID	HGVS	Classification
1374349	NC_000004.11:g.(?186064527)(187630981_?)del	Pathogenic
152921	GRCh38/hg38 4q35.1-35.2(chr4:184924265-186578389)x3	Pathogenic
1807774	GRCh37/hg19 4q35.1-35.2(chr4:185748860-188413920)x1	Pathogenic
253676	GRCh37/hg19 4q35.1-35.2(chr4:185941418-189180194)x1	Pathogenic
395430	GRCh37/hg19 4q35.1-35.2(chr4:186252440-190713591)x1	Pathogenic
59537	GRCh38/hg38 4q35.1-35.2(chr4:185074103-189867552)x1	Pathogenic
59551	GRCh38/hg38 4q35.1-35.2(chr4:185351249-189867552)x1	Pathogenic
1809662	NM_018359.5(UFSP2):c.1376A>C (p.Asn459Thr)	Likely pathogenic
224821	NM_018359.5(UFSP2):c.1373A>G (p.Tyr458Cys)	Likely pathogenic

SpliceAI

655 predictions. Top by Δscore:

Variant	Effect	Δscore
4:185397241:G:GT	donor_gain	1.0000
4:185399027:GA:G	donor_gain	1.0000
4:185399029:G:GG	donor_gain	1.0000
4:185399557:ATCCT:A	acceptor_gain	1.0000
4:185399568:A:AG	acceptor_gain	1.0000
4:185399568:A:C	acceptor_loss	1.0000
4:185399569:G:GG	acceptor_gain	1.0000
4:185399569:GT:G	acceptor_gain	1.0000
4:185399569:GTT:G	acceptor_gain	1.0000
4:185399569:GTTT:G	acceptor_gain	1.0000
4:185399569:GTTTA:G	acceptor_gain	1.0000
4:185399770:GCTG:G	donor_gain	1.0000
4:185399771:CTGGT:C	donor_loss	1.0000
4:185399772:TGGTA:T	donor_loss	1.0000
4:185399774:G:T	donor_loss	1.0000
4:185399775:T:A	donor_loss	1.0000
4:185397144:CTGCA:C	acceptor_loss	0.9900
4:185397145:TGCAG:T	acceptor_loss	0.9900
4:185397146:GCAGG:G	acceptor_loss	0.9900
4:185397147:CAGGT:C	acceptor_loss	0.9900
4:185397148:A:AC	acceptor_loss	0.9900
4:185397149:G:GT	acceptor_loss	0.9900
4:185397298:AGCAG:A	donor_loss	0.9900
4:185397299:GCAG:G	donor_gain	0.9900
4:185397300:CAGG:C	donor_loss	0.9900
4:185397301:AGG:A	donor_loss	0.9900
4:185397302:GG:G	donor_loss	0.9900
4:185397303:GTA:G	donor_loss	0.9900
4:185397304:T:A	donor_loss	0.9900
4:185398936:GGAT:G	acceptor_gain	0.9900

AlphaMissense

1033 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:185398937:G:C	D61H	0.981
4:185399596:C:A	A100D	0.979
4:185398970:G:C	A72P	0.977
4:185398971:C:A	A72E	0.975
4:185398991:T:C	C79R	0.974
4:185399608:C:A	A104D	0.974
4:185399605:T:C	L103P	0.971
4:185398967:G:C	A71P	0.970
4:185398995:T:C	L80P	0.970
4:185399004:T:A	L83H	0.966
4:185398968:C:A	A71E	0.964
4:185399640:T:C	F115L	0.959
4:185399642:T:A	F115L	0.959
4:185399642:T:G	F115L	0.959
4:185398993:C:G	C79W	0.957
4:185399633:T:G	C112W	0.957
4:185399641:T:C	F115S	0.957
4:185399644:T:C	L116P	0.957
4:185398939:T:A	D61E	0.956
4:185398939:T:G	D61E	0.956
4:185399579:T:A	N94K	0.955
4:185399579:T:G	N94K	0.955
4:185399607:G:C	A104P	0.955
4:185398938:A:T	D61V	0.953
4:185397238:C:A	A39E	0.952
4:185399622:T:C	F109L	0.952
4:185399624:T:A	F109L	0.952
4:185399624:T:G	F109L	0.952
4:185398938:A:C	D61A	0.951
4:185399631:T:C	C112R	0.951

dbSNP variants (sampled 300 via entrez): RS1000157102 (4:185396159 C>T), RS1000377933 (4:185396345 G>A,C), RS1000595470 (4:185395893 G>A), RS1000933647 (4:185396707 C>G,T), RS1000949814 (4:185395646 A>G), RS1001194878 (4:185395124 G>A), RS1001373922 (4:185397777 T>C), RS1001377832 (4:185395380 G>A), RS1001426187 (4:185398027 G>A,T), RS10028515 (4:185396363 A>C,G), RS1003046025 (4:185396732 G>A), RS1003796866 (4:185398400 A>G), RS1004042577 (4:185398677 T>C), RS1004614378 (4:185395173 C>T), RS1005393364 (4:185396367 T>C,G)

Disease associations

OMIM: gene MIM:619021 | disease phenotypes: MIM:610551, MIM:142700, MIM:142669

GenCC curated gene-disease

Mondo (3): herpes simplex encephalitis, susceptibility to, 1 (MONDO:0024563), developmental dysplasia of the hip (MONDO:0000158), hip dysplasia, Beukes type (MONDO:0007726)

Orphanet (2): Herpes simplex virus encephalitis (Orphanet:1930), Hip dysplasia, Beukes type (Orphanet:2114)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D000082602	Developmental Dysplasia of the Hip	C05.550.518.384.500; C05.660.297; C16.131.621.297
C564185	Hip Dysplasia, Beukes Type (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

82 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Oxygen	decreases reaction, increases expression	5
Cyclosporine	affects expression, decreases expression, increases expression	4
Formaldehyde	decreases expression, increases expression	3
Valproic Acid	decreases expression, increases expression	3
methylmercuric chloride	decreases expression	2
cobaltous chloride	increases expression, decreases reaction	2
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Cadmium Chloride	increases expression	2
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	decreases reaction, increases expression	1
GSK-J4	increases expression	1
PF-06840003	decreases expression, decreases reaction	1
sotorasib	affects cotreatment, decreases expression	1
4-methyl-7-diethylaminocoumarin	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
deoxynivalenol	decreases expression	1
sodium arsenate	increases abundance, increases expression	1
2-butenal	increases expression	1
beta-lapachone	increases expression	1
arsenite	increases methylation	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
zinc chloride	decreases reaction, increases expression	1
nickel chloride	increases expression	1
1,10-phenanthroline	increases expression	1
cobalt sulfate	increases expression	1
diphenylcyclopropenone	increases expression	1
resorcinol	increases expression	1

Clinical trials (associated diseases)

84 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00208364	PHASE4	TERMINATED	A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement
NCT00208377	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
NCT00208390	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement
NCT00208429	PHASE4	WITHDRAWN	A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement
NCT00208442	PHASE4	COMPLETED	A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement
NCT00208455	PHASE4	TERMINATED	A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
NCT00546598	PHASE4	TERMINATED	Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System
NCT00715026	PHASE4	TERMINATED	Trilogy AB Acetabular Hip System Post Approval Study
NCT00872066	PHASE4	COMPLETED	A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement
NCT00872222	PHASE4	TERMINATED	A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement
NCT00872547	PHASE4	TERMINATED	Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
NCT00872573	PHASE4	TERMINATED	A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement
NCT00872794	PHASE4	TERMINATED	A Single Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery
NCT00873444	PHASE4	TERMINATED	A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing
NCT01134445	PHASE4	TERMINATED	An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
NCT01422564	PHASE4	TERMINATED	Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem
NCT01635166	PHASE4	TERMINATED	Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement Surgery
NCT00208351	PHASE3	TERMINATED	A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement
NCT00208468	PHASE3	TERMINATED	A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement
NCT03107520	EARLY_PHASE1	RECRUITING	Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH
NCT00516555	Not specified	COMPLETED	EBIS: The Eindhoven Breech Intervention Study
NCT00578851	Not specified	COMPLETED	A Clinical Investigation of the C2a-Taper™ Acetabular System
NCT00843258	Not specified	COMPLETED	Treatment for Mild Hip Dysplasia in Newborns
NCT01053299	Not specified	UNKNOWN	Universal Ultrasound-screening for Developmental Dysplasia of the Hip in Newborn
NCT01107340	Not specified	ACTIVE_NOT_RECRUITING	AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study
NCT01285843	Not specified	COMPLETED	Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
NCT01345838	Not specified	COMPLETED	Acetabular Labral Tear in Dysplastic Hips
NCT01437124	Not specified	COMPLETED	Metal Ions in Ceramic on Metal Total Hip Arthroplasty
NCT01866527	Not specified	COMPLETED	Selective Ultrasound Screening for DDH 1991-2006
NCT02162186	Not specified	COMPLETED	Clinical and Radiographic Outcomes of the Corin Tri-Fit Total Hip Replacement
NCT02185365	Not specified	UNKNOWN	Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia
NCT02196818	Not specified	TERMINATED	A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup
NCT02347384	Not specified	COMPLETED	Project JAY THA Registration Study
NCT02399007	Not specified	COMPLETED	A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China
NCT02431871	Not specified	ACTIVE_NOT_RECRUITING	Sequelae of Developmental Dysplasia of the Hip
NCT02503891	Not specified	UNKNOWN	AL-2 MP-1 (Polyimide) Acetabular Liner
NCT02748408	Not specified	RECRUITING	The Medacta International SMS Post-Marketing Surveillance Study
NCT02783274	Not specified	COMPLETED	Actis Total Hip System 2 Year Follow-up
NCT02796768	Not specified	UNKNOWN	Automatic Characterization of the Neonatal Hip Using Ultrasound Imaging
NCT02885831	Not specified	UNKNOWN	Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip